Skip to main content Skip to navigation
CD3 BV421
Product Details
Down Arrow Up Arrow


BD Horizon™
CD3-epsilon; CD3E; Leu4; T-cell surface antigen T3/Leu-4 epsilon chain; T3E
Human
Mouse BALB/c IgG1, κ
Human Thymocytes
Flow cytometry
25.0 μg/mL
5 μL
II T118; III T492
916
ASR


659448 Rev. 1
Antibody Details
Down Arrow Up Arrow
SK7

The CD3 antibody, clone SK7, is derived from the hybridization of NS-1 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with human thymocytes.

The CD3 antibody reacts with the epsilon chain of the CD3 antigen/TCR complex. This complex is composed of at least six proteins that range in molecular weight from 20 to 30 kilodaltons (kDa). The antigen recognized by CD3 antibodies is noncovalently associated with either α/β or γ/δ TCR (70 to 90 kDa).

659448 Rev. 1
Format Details
Down Arrow Up Arrow
BV421
The BD Horizon Brilliant Violet™ 421 (BV421) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye has an excitation maximum (Ex Max) of 407-nm and an emission maximum (Em Max) at 423-nm. Driven by BD innovation, BV421 is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 420-nm (e.g., a 431/28-nm or 450/50-nm bandpass filter). BV421 is an ideal alternative for V450 as it is approximately ten times brighter with less spillover into the BV510/V500 detector. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BV421
Violet 405 nm
407 nm
423 nm
659448 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "659448" on CiteAb

Development References (11)

  1. Brenner M, Groh V, Porcelli S, et al. Knapp W, Dörken B, Gilks W, et al, ed. Leucocyte Typing IV: White Cell Differentiation Antigens. New York: Oxford University Press; 1989:1049-1053.
  2. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
  3. Clevers H, Alarcón B, Wileman T, Terhorst C. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annual Rev Immunol. 1988; 6:629. (Biology).
  4. Clinical and Laboratory Standards Institute. 2005. (Biology).
  5. Garson JA, Beverley PCL, Coakham HB, Harper EJ. Monoclonal antibodies against human T lymphocytes label Purkinje neurones of many species. Nature. 1982; 298:375-377. (Biology).
  6. Haynes BF. Summary of T-cell studies performed during the Second International Workshop and Conference on Human Leukocyte Differentiation Antigens. In: Reinherz EL. Ellis L. Reinherz .. et al., ed. Leukocyte typing II. New York: Springer-Verlag; 1986:3-30.
  7. Kaneoka H, Perez-Rojas G, Sasasuki T, Benike CJ, Engleman EG. Human T lymphocyte proliferationinduced by a pan-T monoclonal antibody (anti-Leu-4): heterogeneity of response is a function ofmonocytes. J Immunol. 1983; 131:158-164. (Biology).
  8. Knowles RW. Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, ed. Leukocyte Typing II. Human T Lymphocytes. New York, NY: Springer-Verlag; 1986:259-288.
  9. Lanier LL, Allison JP, Phillips JH. Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. J Immunol. 1986; 137(8):2501-2507. (Biology). View Reference
  10. Reichert T, DeBruyere M, Deneys V, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol. 1991; 60(2):190-208. (Biology). View Reference
  11. van Dongen JJM, Krissansen GW, Wolvers-Tettero ILM, et al. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies. Blood. 1988; 71:603-612. (Biology).
View All (11) View Less
659448 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.